Abstract
Aim: Several studies have demonstrated that a proinflammatory cytokine resistin is an important contributor to cardiovascular risk in patients with chronic kidney disease (CKD), as well as its ability to stimulate overexpression of CD36 in vitro. Adenylate cyclase-associated protein 1 (CAP1) is a recently identified receptor for human resistin that mediates proinflammatory effects of resistin. Since CAP1 has not been previously evaluated in CKD, the aim of this study was to determine peripheral blood mononuclear cells (PBMCs) CAP1, CD36, resistin mRNA and plasma resistin concertation in CKD patients.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
